Cancer therapy developer Artiva Biotherapeutics files to hold IPO on Nasdaq
By Val Kennedy, Artiva Biotherapeutics (ARTV), which is developing cell-based therapies to treat cancer, has filed to hold an initial public offering on Nasdaq. The biotech group didn’t disclose the size and pricing of the intended deal. The company hopes to list its shares on Nasdaq under the symbol ARTV, according to its filing. Goldman[…]